The Estonia Pharmaceutical Market is Segmented by Therapeutic Category (Anti-Infectives, Cardiovascular, Gastrointestinal, Anti-Diabetic, Respiratory, Dermatological, Musculoskeletal System, Nervous System, and Other Therapeutic Categories) and Drug Type (Prescription Drugs (Branded Drugs and Generic Drugs) and OTC Drugs). For Each Segment, The Market Size and Forecast are Provided in Terms of Value (USD).

The Estonian pharmaceutical market, valued at €528.14 million in 2025, is projected to experience robust growth, driven by factors such as an aging population necessitating increased medication use, rising prevalence of chronic diseases like cardiovascular conditions and diabetes, and increasing healthcare expenditure. The market's Compound Annual Growth Rate (CAGR) of 6.55% from 2025 to 2033 signifies a consistently expanding market opportunity. Growth is further fueled by the increasing adoption of innovative therapies, advancements in drug discovery and development, and a growing awareness of self-medication and preventive healthcare amongst the Estonian population. The market is segmented by therapeutic category (anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, respiratory, dermatologicals, musculoskeletal, nervous system, and others) and drug type (prescription—branded and generic—and over-the-counter (OTC) drugs). Major players like AbbVie, Merck, Novartis, Pfizer, Sanofi, Roche, AstraZeneca, Eli Lilly, and GlaxoSmithKline are actively competing within this growing market, indicating a high level of investment and competition in research, development, and distribution. The Estonian pharmaceutical market's growth is influenced by both opportunities and challenges. Government regulations, pricing policies, and healthcare reforms will play crucial roles in shaping the market trajectory. Furthermore, the availability of generic drugs and increasing pressure on healthcare costs could moderate price growth. Nevertheless, the ongoing investment in healthcare infrastructure and the growing focus on improving public health outcomes create a favorable environment for sustained market expansion. Market segmentation analysis reveals significant opportunities within the chronic disease therapeutic areas, reflecting the demographic shifts and healthcare needs of the Estonian population. Future growth will likely be further propelled by increased access to innovative medications and improved healthcare services. Recent developments include: June 2024: Takeda Pharmaceutical Company Limited received the EC approval for its FRUZAQLA (fruquintinib) drug as a monotherapy indicated for treating adults with metastatic colorectal cancer (mCRC)., January 2024: Pfizer Inc. received approval from the European Commission (EC) for its TALZENNA (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI (enzalutamide), for treating adults with metastatic castration-resistant prostate cancer (mCRPC).. Key drivers for this market are: Rising Healthcare Expenditure, Rising Incidence of Chronic Disease. Potential restraints include: Rising Healthcare Expenditure, Rising Incidence of Chronic Disease. Notable trends are: The Anti-diabetic Segment is Expected to Register Significant Growth During the Forecast Period.

The Estonia pharmaceutical market was valued at USD 525.82 Million in 2024, driven by the rising incidence of chronic diseases and government initiatives across the region. The market is anticipated to grow at a CAGR of 6.55% during the forecast period of 2025-2034, with the values likely to reach USD 991.68 Million by 2034.

Estonia Pharmaceutical Market size was valued at $ 485 Mn in 2024 and is expected to reach $ 750 Mn by 2032, growing at a CAGR of 5.7% from 2026 to 2032.Estonia Pharmaceutical Market: Definition/ OverviewPharmaceuticals are substances that are employed to diagnose, treat, or prevent diseases and other medical conditions. They include a wide variety of products, including tablets, capsules, injections and topical formulations. Pharmaceuticals, which are the result of extensive scientific research, must meet stringent safety and efficacy standards before they can be approved for use by health authorities around the world.

Estonia Pharmaceutical comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to forecast potential market management during the forecast period between 2025 - 2033.

In 2022, the share of generics in respective pharmaceutical market in Estonia decreased by *** percent of sales volume in the same market (***** percent) since 2021. Nevertheless, the last two years recorded a significant higher share than the preceding years.Find more key insights for the share of generics in respective pharmaceutical market in countries like France, Czechia, and Portugal.

Pharmaceutical Goods Market Size Value Per Capita in Estonia, 2021 Discover more data with ReportLinker!

Estonia EE: Pharmaceutical Industry: Export Market Share data was reported at 0.015 % in 2020. This records a decrease from the previous number of 0.017 % for 2019. Estonia EE: Pharmaceutical Industry: Export Market Share data is updated yearly, averaging 0.015 % from Dec 1996 (Median) to 2020, with 25 observations. The data reached an all-time high of 0.038 % in 1997 and a record low of 0.010 % in 2006. Estonia EE: Pharmaceutical Industry: Export Market Share data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Estonia – Table EE.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Estonia, GBARD figures come from budget data from 2016 onward, whereas they were previously estimated from R&D survey data.

In 2023, the number of enterprises in the basic pharmaceutical products manufacturing industry in Estonia stood at about five. Between 2021 and 2023, the number of enterprises rose by approximately three.

Estonia EE: Pharmaceutical Industry: Total Imports data was reported at 795.816 USD mn in 2021. This records an increase from the previous number of 643.830 USD mn for 2020. Estonia EE: Pharmaceutical Industry: Total Imports data is updated yearly, averaging 321.449 USD mn from Dec 1995 (Median) to 2021, with 27 observations. The data reached an all-time high of 795.816 USD mn in 2021 and a record low of 49.919 USD mn in 1995. Estonia EE: Pharmaceutical Industry: Total Imports data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Estonia – Table EE.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Estonia, GBARD figures come from budget data from 2016 onward, whereas they were previously estimated from R&D survey data.

In 2022, the pharmaceutical consumption of antidepressants in Estonia increased by 3.8 defined daily doses per 1,000 inhabitants per day (+9.34 percent) since 2021. With 44.5 defined daily doses per 1,000 inhabitants per day, the consumption thereby reached its highest value in the observed period. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

Estonia EE: Pharmaceutical Industry: Total Exports data was reported at 129.940 USD mn in 2021. This records an increase from the previous number of 106.467 USD mn for 2020. Estonia EE: Pharmaceutical Industry: Total Exports data is updated yearly, averaging 48.917 USD mn from Dec 1995 (Median) to 2021, with 27 observations. The data reached an all-time high of 129.940 USD mn in 2021 and a record low of 19.663 USD mn in 1995. Estonia EE: Pharmaceutical Industry: Total Exports data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Estonia – Table EE.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Estonia, GBARD figures come from budget data from 2016 onward, whereas they were previously estimated from R&D survey data.

The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transitions which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference for generics compared to their branded versions. As a result of these transformations; the need for a user friendly, robust and comprehensive pharmaceutical market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the pharmaceutical market in some form or the other.

IMARC Group, one of the world’s leading research and advisory firms, introduces a new and revolutionary way to understand and evaluate the global pharmaceutical market with its Microsoft Excel based report entitled “Global Pharmaceutical Market Report & Forecast: 2012-2017”. This report provides an analytical and statistical insight into the global pharmaceutical market. The study, which has been undertaken using desk based as well as primary market research has analyzed the following aspects of the global pharmaceutical market.

What We Have Achieved in This Report?

Regions Covered: Global, North America, Europe, Asia Pacific, Latin America & Caribbean and Middle East & Africa

Countries Covered in Each Region

North America: United States and Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Netherlands, Poland, Greece, Belgium, Switzerland, Austria, Sweden, Portugal, Hungary, Romania, Denmark, Czech Republic, Finland, Ireland, Norway, Slovakia, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Luxembourg and Estonia

Asia Pacific: Japan, China, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Pakistan, Vietnam, Bangladesh, Hong Kong, New Zealand, Malaysia and Singapore

Latin America & Caribbean:Brazil, Mexico, Venezuela, Argentina, Puerto Rico, Colombia, Chile, Ecuador, Peru, Dominican Republic and Uruguay

Middle East & Africa: South Africa, Egypt, Saudi Arab, Algeria, Morocco, United Arab Emirates Lebanon, Tunisia, Jordan and Kuwait

Focus of the Analysis:

• Historical sales performance (2007-2011) for each country
• Historical sales performance (2007-2011) for each region
• Sales forecast (2012-2017) for each country
• Sales forecast (2012-2017) for each region
• Sales performance of key manufacturers for each country (2007-2011)
• Sales performance of key therapeutic areas for each country (2007-2011)
• Country wise sales breakup for each region (2007-2011)
• Country wise sales breakup forecast for each region (2012-2017)

Key Questions Answered;

• What was the historical performance of the global pharmaceutical market?
• Which are the key regions and countries in the global pharmaceutical market?
• Which are the largest pharmaceutical markets in the world?
• Which are the fastest growing pharmaceutical markets in the world?
• Which markets are expected to witness the slowest growth in the coming years?
• Which countries represent the key markets for each region?
• What has been the performance of various therapeutic classes in each country?
• Who are the top pharmaceutical manufacturers in each country?
• What are the market shares of the top pharmaceutical manufacturers in each country?

Why You should Buy This Report?

• To gain a comprehensive understanding on the historical, current and future pharmaceutical market trends across 70 countries in 6 regions.
• To identify potential regions, countries, therapeutic areas, partners and competitors for market entry and expansion plans.
• As a tool for developing investment strategies by identifying the biggest winners and losers across various regions and countries.
• To ensure a successful M&A and partnership strategy by identifying therapeutic areas and companies with the most promising outlook.

Estonia EE: BERD Performed: Current PPP: Pharmaceutical Industry data was reported at 3.731 USD mn in 2021. This records an increase from the previous number of 1.248 USD mn for 2019. Estonia EE: BERD Performed: Current PPP: Pharmaceutical Industry data is updated yearly, averaging 1.636 USD mn from Dec 2010 (Median) to 2021, with 11 observations. The data reached an all-time high of 6.229 USD mn in 2011 and a record low of 0.457 USD mn in 2010. Estonia EE: BERD Performed: Current PPP: Pharmaceutical Industry data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Estonia – Table EE.OECD.MSTI: Business Enterprise Investment on Research and Development: OECD Member: Annual.

In Estonia, GBARD figures come from budget data from 2016 onward, whereas they were previously estimated from R&D survey data.

In 2022, the number of enterprises in the pharmaceutical preparations manufacturing industry in Estonia did not change in comparison to the previous year. The number of enterprises remained at 12 enterprises. Only active units which either had turnover or employment at any time during the reference period should be included.

The demographic trend of an ageing European population is reshaping the retail market for medical supplies, notably due to the increased prevalence of issues like reduced mobility and hearing impairment among seniors. This shift bolsters the sales of medical and orthopaedic supplies across the continent, particularly as seniors become a more significant consumer segment for these products as the ageing population climbs. Traditional pharmacy chains are diversifying into the medical devices sector, offering items like blood pressure monitors at competitive prices and challenging specialised retailers. Online retailers compound the competition with lower-priced offerings attributable to their minimal operational expenses. Major companies are strategically acquiring smaller businesses to enhance their global reach and strengthen their European market standing. These trends underline a robust market environment catering to the senior demographic's needs, with expanding product ranges, competitive pricing and industry consolidation contributing to overall profitability and dynamism within the sector. However, online retailers are capturing a larger market share by offering basic medical supplies at competitive prices and providing a more convenient shopping experience. This shift is leading to a drop in revenue within the traditional medical supply industry. Industry revenue is forecast to grow at a compound annual rate of 1.2% over the five years through 2025 to €430 billion, including an estimated hike of 0.9% in 2025, while the average industry profit margin is expected to dip slightly to 9.4% amid climbing purchase costs. A hike in the hearing aid market is likely because of rising healthcare standards. In response, industry trends suggest medical orthopaedic retailers will diversify their offerings and add services like hearing tests to enhance market presence. Retailers are capitalising on the opportunity to facilitate increased hearing aid sales through the provision of comprehensive services, meeting the evolving demands of an ageing population in pursuit of hearing health solutions. Companies in the industry should rally behind the proposed EU Critical Medicines Act to strengthen the pharmaceutical supply chain and the industry's future. Industry revenue is forecast to swell at a compound annual rate of 4.6% over the five years through 2030 to €538.5 billion.

Estonia Imports from Georgia of Pharmaceutical products was US$124.29 Thousand during 2024, according to the United Nations COMTRADE database on international trade. Estonia Imports from Georgia of Pharmaceutical products - data, historical chart and statistics - was last updated on October of 2025.

The Estonian pharmaceutical rubber articles market rose sharply to $2.9M in 2024, picking up by 15% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). Overall, consumption recorded resilient growth. Pharmaceutical rubber articles consumption peaked at $7.2M in 2022; however, from 2023 to 2024, consumption remained at a lower figure.

Between 2016 and 2022, the generic pharmaceuticals market value in the community pharmacies market in Estonia fluctuated, with the generic market in community pharmacies standing at some 19.5 percent in 2022. This statistic displays the market value share of generic pharmaceuticals in community pharmacies in Estonia from 2000 to 2022.

Estonia Foreign Direct Investment Income: Outward: Total: Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations data was reported at 0.000 EUR mn in 2023. Estonia Foreign Direct Investment Income: Outward: Total: Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations data is updated yearly, averaging 0.000 EUR mn from Dec 2023 (Median) to 2023, with 1 observations. The data reached an all-time high of 0.000 EUR mn in 2023 and a record low of 0.000 EUR mn in 2023. Estonia Foreign Direct Investment Income: Outward: Total: Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Estonia – Table EE.OECD.FDI: Foreign Direct Investment Income: by Industry: OECD Member: Annual. Reverse investment: Netting of reverse investment in equity (when a direct investment enterprise acquires less than 10% equity ownership in its parent) and reverse investment in debt (when a direct investment enterprise extends a loan to its parent) is applied in the recording of total inward and outward FDI transactions and positions. Treatment of debt transactions and positions between fellow enterprises: directional basis according to the residency of the ultimate controlling parent (extended directional principle). FDI transactions and positions by partner country and/or by industry are available including and excluding resident Special Purpose Entities (SPEs). The dataset 'FDI statistics by parner country and by industry - Summary' contains series including resident SPEs only. Valuation method used for listed inward and outward equity positions: Market value. Valuation method used for unlisted inward equity positions: Own funds at book value. Valuation method used for unlisted outward equity positions: Net asset value including goodwill and intangibles, Historic or acquisition cost, Book value. Valuation method used for inward and outward debt positions: Nominal value .; FDI statistics are available by geographic allocation, vis-à-vis single partner countries worldwide and geographical and economic zones aggregates. Partner country allocation can be subject to confidentiality restrictions. Geographic allocation of inward and outward FDI transactions and positions is according to the immediate counterparty. Inward FDI positions according to the ultimate counterparty (the ultimate investing country) are also available and publishable. In the dataset 'FDI statistics by parner country and by industry - Summary', inward FDI positions are showed according to the UIC. Intercompany debt between related financial intermediaries, including permanent debt, are excluded from FDI transactions and positions. Direct investment relationships are identified according to the criteria of the Framework for Direct Investment Relationships (FDIR) method. Debt between fellow enterprises are partially covered. Collective investment institutions are partially covered as direct investment enterprises. Non-profit institutions serving households are covered as direct investors. FDI statistics are available by industry sectors according to ISIC4 classification. Industry sector allocation can be subject to confidentiality restrictions. Inward FDI transactions and positions are allocated to the activity of the resident direct investment enterprise. Outward FDI transactions are allocated according to the activity of the non resident direct investment enterprise. Outward FDI positions are allocated according to the activity of the non resident direct investment enterprise. Statistical unit: Enterprise.